Xilio Therapeutics (XLO) Assets (2020 - 2026)

Xilio Therapeutics has disclosed Assets across 7 years of filings, most recently posting $154.3 million for Q2 2026.

• In Q2 2026, Assets rose 15.28% year-over-year to $154.3 million; the TTM figure through Jun 2026 stood at $154.3 million (up 15.28% YoY), while the FY2025 annual figure was $154.7 million, up 117.64% from the prior year.
• Assets came in at $154.3 million for Q2 2026 at Xilio Therapeutics, down from $163.5 million in the prior quarter.
• In the past five years, Assets ranged from a high of $196.4 million in Q1 2022 to a low of $60.9 million in Q4 2023.
• Average Assets over 5 years is $120.9 million, with a median of $122.6 million recorded in 2023.
• Year-over-year, Assets plunged 56.22% in 2023 and soared 117.64% in 2025.
• Over 5 years, Assets stood at $139.2 million in 2022, then sank by 56.22% to $60.9 million in 2023, then increased by 16.66% to $71.1 million in 2024, then soared by 117.64% to $154.7 million in 2025, then slipped by 0.28% to $154.3 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $154.3 million in Q2 2026, $163.5 million in Q1 2026, and $154.7 million in Q4 2025.